Neurogene Inc. — Director's Dealing 2019

Oct 15, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Neoleukin Therapeutics, Inc. (NLTX)
CIK: 0001404644
Period of Report: 2019-10-10

Reporting Person: Williams Lewis T (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-10-10	Stock Option (right to buy)	$2.82	A	22000	Acquired	2029-10-09	Common Stock (22000)	Direct

Footnotes

F1: The options will vest as to 1/3 of the total number of shares underlying the options on each of October 10, 2020, October 10, 2021 and October 10, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.